Tirzepatide is an FDA-approved dual GLP-1 and GIP receptor agonist for chronic weight management, delivered as a weekly subcutaneous injection inside a medically supervised medical programme at our Miami clinic, with eligibility decided by BMI and clinical history.
Book consultationEligibility is based on BMI and clinical history, never on patient preference alone. Adults with BMI 30 or higher, or 27 or higher with a weight-related comorbidity such as hypertension, dyslipidaemia or type 2 diabetes, may be candidates. Personal or family history of medullary thyroid cancer, MEN-2, pancreatitis or severe gastroparesis are exclusions. The final decision is made by Ronal Perdomo Lugo, APRN, FNP-C after consultation, examination and baseline labwork.
Most patients experience some gastrointestinal effects during dose escalation, especially nausea, reduced appetite, constipation or diarrhoea. These are usually mild to moderate and improve over weeks. Less common but more serious risks include pancreatitis, gallbladder issues, severe dehydration and severe gastroparesis. We review every patient's red-flag symptoms in writing before the first dose, and a same-week response is the clinic standard for any concerning symptom.
Diet and exercise are the foundation of any weight-management plan and remain so during tirzepatide therapy. The medication does not replace lifestyle work; it supports adherence by reducing appetite signalling and food preoccupation in patients for whom willpower-based approaches have repeatedly failed. Without nutritional coaching, adequate protein, hydration and movement, results are inferior, harder to sustain, and more prone to muscle loss. The programme treats medication and lifestyle as inseparable.
Book a consultation with Ronal Perdomo, APRN, FNP-C (Aesthetic Nurse Practitioner) to design your personalised plan.
Book consultation